• Descriptive and clinical data were obtained from the records of outpatients that had picked up their medication from Hospital Pharmacy Service.
RESULTS
• Descriptive and clinical data were obtained from the records of outpatients that had picked up their medication from Hospital Pharmacy Service.
• Descriptive statistical analyses of qualitative and quantitative data were made with SPSS program.
Erythropoietin stimulating agents are used to treat anaemia associated with chronic kidney disease (CKD) and anaemia in patients receiving chemotherapy.
The purpose of this study was to analyze erythropoietin stimulating agents treatment in patients with CKD and oncology diseases.
In patients with chronic kidney disease, hemoglobin levels remained stable during the period. Although the levels were lower than 11 g/dl in most of them, no significant clinical symptoms were observed.
The use of erythropoietin stimulating agents lightly improved the hemoglobin values in oncology patients, although blood transfusions were needed for half of the patients. • Oncology:  53.8% were men, mean age: 68.7 years-old (SD 11.2). 
